A MULTICENTER, SINGLE-ARM, THREE COHORT, PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN PATIENTS WITH ACTIVE BRAIN METASTASES FROM HER3-EXPRESSING ADVANCED BREAST CANCER AND NON–SMALL CELL LUNG CANCER, AND IN PATIENTS WITH LEPTOMENINGEAL CARCINOMATOSIS FROM HER3-EXPRESSING ADVANCED SOLID TUMORS (The TUXEDO-3 Study)

Medica Scientia Innovation Research S.L.0 个研究点目标入组 60 人开始时间: 2023年7月4日最近更新: 2024年7月22日

适应症

试验速览

阶段: 1 期
状态: 招募中
发起方
入组人数: 60

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

年龄范围: 18 至 65+（—）
性别: All

入选标准

•Patient must be capable to understand the purpose of the study and have signed written informed consent form (ICF) prior to beginning specific protocol procedures., Patient has adequate bone marrow, liver, and renal function: Renal: serum creatinine = 1.5 x ULN or creatinine clearance = 50 mL/min/1.73 m2 based on Cockcroft-Gault glomerular filtration rate estimation for patients with creatinine levels above institutional normal., Participants in cohort 1 and cohort 2 must have received at least one prior line of systemic treatment in the advanced setting. Note I: prior systemic treatments for BC eligible patients would be defined as follows: TNBC patients must have received at least one line of prior systemic therapy for advanced disease. Luminal BC patients must have received at least one line of ET and one line of CT in the advanced setting. HER2[+] BC patients must have progressed on at least two previous treatments with HER2-targeted therapies in the advanced setting. Note II: prior systemic treatments for aNSCLC eligible patients would be defined as follows: Patients without activating driver alterations must have received at least one prior line of standard of care systemic therapy for locally advanced or metastatic disease. Patients with activating driver alterations must have received at least one prior line of an approved genotype-directed therapy. Participants with EGFR T790M mutation who received first-line treatment with erlotinib, gefitinib, afatinib, or dacomitinib must have received second-line treatment with osimertinib and have documentation of radiological disease progression., Resolution of all acute toxic effects of prior anti-cancer therapy to grade = 1 as determined by the US National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 (v.5.0). Note: Except for alopecia or other toxicities not considered a safety risk for the patient at investigator’s discretion., For women of childbearing potential: agreement to remain abstinent (must refrain from heterosexual intercourse) or use highly effective contraceptive methods, or two effective contraceptive methods, as defined in the CSP, during the treatment period and for at least 7 months after the last dose of study treatment, whichever is longer. Women of childbearing potential must have a negative serum pregnancy test within 14 days before study treatment initiation (with result available prior to dosing) and must agree to refrain from donating eggs during the entire study treatment period and for 7 months after the last administration of the study drug., Being male subjects, surgically sterile or having agreed with true abstinence (must refrain from heterosexual intercourse), or whose female partners are willing to agree with true abstinence or use barrier contraceptive measures mentioned above during the entire study treatment period and for 4 months after the last administration of the study drug. Males must agree to refrain from donating sperm during the entire study treatment period and for 4 months after the last administration of the study drug., Patient must be accessible for treatment and follow-up., Cohort 1 and cohort 2 specific inclusion criteria: Histologically documented BC (cohort 1) or NSCLC of squamous or non-squamous histologic types (cohort 2)., Cohort 1 and cohort 2 specific inclusion criteria: Newly diagnosed BM or BM progressing after local treatment., Cohort 1 and cohort 2 specific inclusion criteria: Meas

排除标准

•Current participation in another therapeutic clinical trial., Pregnant or lactating women., Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study., Current known infection with hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients with past HBV infection or resolved HBV infection (defined as having a negative hepatitis B surface antibody [HBsAg] test and a positive hepatitis B core antibody [HBcAb] test, accompanied by a negative HBV DNA test) are eligible. Patients positive for HCV antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA., Known human immunodeficiency virus (HIV) infection that is not well controlled. All of the following criteria are required to define an HIV infection that is well controlled: undetectable viral RNA, CD4+ count =350, no history of AIDS-defining opportunistic infection within the past 12 months, and stable for at least 4 weeks on the same anti-HIV medications (meaning there are no expected further changes in that time to the number or type of antiretroviral drugs in the regimen). If an HIV infection meets the above criteria, monitoring of viral RNA load and CD4+ count is recommended., History of a major surgical procedure (defined as requiring general anesthesia) or significant traumatic injury within 21 days prior to randomization, or patients who have not recovered from the side effects of any major surgery., A history of uncontrolled seizures, CNS disorders or serious and/or unstable pre-existing psychiatric disability judged by the investigator to be clinically significant and adversely affecting compliance to study drugs or interfering with subject safety., Patients requiring concomitant use of chronic systemic (intravenously [IV] or oral) corticosteroids at doses higher than 8 mg dexamethasone per day or other immunosuppressive medications except for managing adverse events (AEs), including immune-related adverse events (irAEs) for patients that received immunotherapy in a previous line; (inhaled steroids or intra articular steroid injections are permitted in this study). Note: The use of stable corticosteroid therapy in patients with BM can be discussed with the Medical Monitor., Patients with known substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject’s participation in the clinical study or evaluation of the clinical study results., Participants who are unable or unwilling to comply with the requirements of the protocol in the opinion of the investigator., Treatment with approved or investigational cancer therapy within 14 days prior to initiation of study drug., Patients have a concurrent malignancy or malignancy within five years of study enrollment with the exception of carcinoma in situ of the cervix, non-melanoma skin carcinoma, or stage I uterine cancer. For other cancers considered to have a low risk of recurrence, discussion with the Medical Monitor is required., Previous systemic therapy with any anti-HER3 directed drug., Known allergy or hypersensitivity to HER3-DXd or any of the drug components., Radiotherapy or limited-field palliative radiotherapy within seven days prior to study enrolment, or patients who have not recovered from radiotherapy-related toxicities to baseline or grade

研究者

发起方

Medica Scientia Innovation Research S.L.

相似试验

已完成

2 期

A PHASE 2, SINGLE-ARM, MULTI-COHORT, MULTI-CENTER TRIAL TO DETERMINE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAAggressive Non-Hodgkin B-Cell Lymphomafast growing B-cell cancer of the lymph nodes1002532010025322

NL-OMON52985Celgene Corporation6

进行中（未招募）

不适用

Study to compare the effect of two different injection techniques used for Dysport treatment of patients with upper limb spasticity post stroke or traumatic brain injurypper limb spasticity post stroke or traumatic brain injury.MedDRA version: 17.0Level: LLTClassification code 10048970Term: Arm spasticitySystem Organ Class: 100000004852

EUCTR2011-005375-16-FIInstitut Produits Synthèse (IPSEN) AB272

进行中（未招募）

1 期

EUCTR2011-005375-16-DKInstitut Produits Synthèse (IPSEN) AB100

进行中（未招募）

不适用

Study to compare the effect of two different injection techniques used for Dysport treatment of patients with upper limb spasticity post stroke or traumatic brain injury

EUCTR2011-005375-16-SEInstitut Produits Synthèse (IPSEN) AB272

进行中（未招募）

1 期

Multicenter, triple-arm, single-stage, phase II trialto determine the preliminary efficacy and safety of RAD001in patients with histological evidence of progressive or metastaticbone or soft tissue sarcomas

EUCTR2007-005294-60-DEovartis Pharma GmbH60